William Hill (OTCMKTS:WIMHY) versus SWEDISH ORPHAN/S (OTCMKTS:SWTUY) Financial Comparison

SWEDISH ORPHAN/S (OTCMKTS:SWTUY) and William Hill (OTCMKTS:WIMHY) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Earnings & Valuation

This table compares SWEDISH ORPHAN/S and William Hill’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SWEDISH ORPHAN/S	$763.19 million	8.71	$134.73 million	$0.50	48.76
William Hill	$1.58 billion	2.49	-$34.35 million	$0.54	27.78

SWEDISH ORPHAN/S has higher earnings, but lower revenue than William Hill. William Hill is trading at a lower price-to-earnings ratio than SWEDISH ORPHAN/S, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

SWEDISH ORPHAN/S has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, William Hill has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for SWEDISH ORPHAN/S and William Hill, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SWEDISH ORPHAN/S	0	0	0	0	N/A
William Hill	0	0	0	0	N/A

Profitability

This table compares SWEDISH ORPHAN/S and William Hill’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SWEDISH ORPHAN/S	25.75%	29.63%	18.74%
William Hill	N/A	N/A	N/A

Summary

SWEDISH ORPHAN/S beats William Hill on 6 of the 9 factors compared between the two stocks.

About SWEDISH ORPHAN/S

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

About William Hill

William Hill PLC, a sports betting and gaming company, provides sports betting and gaming services in the United Kingdom, the United States, and internationally. It operates through retail, online, and US segments. The company operates licensed betting offices (LBOs) that offers sports betting services on horse racing, football, greyhounds, and other sports, as well as gaming machines. It also provides online sports betting, casino, poker, and other gaming products, as well as telephone betting services. William Hill PLC was formerly known as William Hill Limited and changed its name to William Hill PLC in May 2002. The company was founded in 1934 and is based in London, United Kingdom. As of April 22, 2021, William Hill PLC operates as a subsidiary of Caesars Entertainment, Inc.